We are witnessing a proliferation of profit-seeking businesses, venture capital investment, and associated public relations and marketing—as well as national trends of decriminalizing and even legalizing psychedelic compounds for personal use and clinical services. FDA approval of MDMA-assisted therapy appears to be on the horizon. The genie is truly out of the bottle.
Along with expanding our understanding of the potential clinical benefits of these compounds, it is essential for clinicians to understand their dangers. Harm can come from multiple angles, including reenactments of trauma and systemic racism and other injustices from which psychotherapy can never be fully insulated. Recent press highlighting exploitation and failures to competently treat the most vulnerable patients in the vulnerable states associated with these medicines highlights the need for clinicians interested in PAP to fully understand the complexities that may arise and the steps they can take to prevent or reduce various sources of harm.
Accordingly, this course will address the research on the benefits of psychedelics for treating mental health disorders. It will explore the critical issues that clinicians must recognize and address to provide competent, safe and trauma-informed PAP. Finally, it will introduce trainings and organizations that promote effective and ethical work. We are pleased to provide options for both in-person and virtual attendance. Join colleagues from around the world to advance your knowledge and confidence in this burgeoning field!
Sign up with your email to receive news and updates.